Pharmacogenetic loci

Dahl, M. L., Yue, Q. Y. etal. (1995). Genetic analysis oftheCYP2D locus in relation to debriso-quine hydroxylation capacity in Korean, fapanese and Chinese subjects. Pharmacogenetics, 5(3), 159-64. 

Ingelman-Sundberg, M. and W.E. Evans, "Unraveling the Functional Genomics of the Human CYP2D6 Gene Locus," Pharmacogenetics, 11, 553-554 (2001). 

Lindberg RL, Juvonen R, Negishi M (1992) Molecular characterization of the murine Coh locus an amino add difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh, Pharmacogenetics 2 32-37... 

Urano, W., Taniguchi, A., Yamanaka, H., et al. (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 12, 183-190. 

Nebert DW, Petersen DD, Puga A. Human AH locus polymorphism and cancer inducibility of CYP1A1 and other genes by combustion products and dioxin. Pharmacogenetics 1991 1 (2) 68—78. 

Linder MW, Valdes R Jr, Stubbins MJ, Harries LW, Smith G, Tarbit MH, et al. Pharmacogenetics in the practice of laboratory medicine. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Mol Diagn 1999 4 365-79. 

Suzuki A, Mihara K, Kondo T, et al. The relationship between dopamine D2 receptor polymorphism at the TaqlA locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 2000 l0f4) 335 41. 

The APOE locus is not only associated with poor response to cholesterol-lowering drugs, but is also associated with a higher risk of lower age of onset in Alzheimer s disease [18]. More differentiated pharmacogenetic tests will be offered on APOE. Moreover, neurodegenerative diseases are in the focus of many pharmaceutical companies. 

Chang, C., D.R. Smith, VS. Prasad, C.L. Sidman, D.W. Nebert, and A. Puga (1993). Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. Pharmacogenetics 3, 312-321. 

I. Koch, M. Haberl et at. (2001). Genomic organization of the human CYP3A locus Identification of a new, inducible CYP3A gene. Pharmacogenetics... 

Ordovas, J.M., and Mooser, V. (2002) The APOE Locus and the Pharmacogenetics of Lipid Response, Curr. Opin. Lipi-dol. 13, 113-117. 

Imai J, leiri I, Mamiya K, Miyahara S, Furuumi H, Nanba E et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients Genetic analysis of the CYP2C9 locus. Pharmacogenetics 10(1), 85-89,2000. 

---